Celsion (CLSN) Rating Increased to Buy at Zacks Investment Research

Celsion (NASDAQ:CLSN) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research note issued on Thursday. The firm currently has a $3.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 9.09% from the company’s previous close.

According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “

Separately, ValuEngine downgraded shares of Celsion from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd.

Celsion traded up $0.17, reaching $2.75, on Thursday, MarketBeat Ratings reports. The stock had a trading volume of 797,839 shares, compared to its average volume of 266,183. The firm has a market cap of $46.30 million, a PE ratio of -1.15 and a beta of 1.68. Celsion has a 1-year low of $2.61 and a 1-year high of $2.61.

Celsion (NASDAQ:CLSN) last released its quarterly earnings results on Friday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.05. The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative net margin of 3,897.86% and a negative return on equity of 112.83%. analysts expect that Celsion will post -2.86 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Celsion stock. Virtu Financial LLC bought a new position in Celsion Co. (NASDAQ:CLSN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned about 0.24% of Celsion at the end of the most recent quarter. Institutional investors own 3.91% of the company’s stock.

Celsion Company Profile

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply